Coherus BioSciences (CHRS) Scheduled to Post Earnings on Wednesday

Coherus BioSciences (NASDAQ:CHRS) will be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The company had revenue of $64.98 million during the quarter, compared to analysts’ expectations of $57.08 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Price Performance

Shares of NASDAQ:CHRS traded up $0.04 on Tuesday, reaching $0.71. The company’s stock had a trading volume of 1,156,660 shares, compared to its average volume of 2,625,479. The stock has a market capitalization of $81.81 million, a P/E ratio of -1.67 and a beta of 0.69. Coherus BioSciences has a 52-week low of $0.66 and a 52-week high of $3.73. The stock’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.48.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a report on Monday, September 16th. UBS Group downgraded shares of Coherus BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $4.00 to $1.50 in a research report on Friday, August 16th. Finally, StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.13.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.